0000000000798438

AUTHOR

Matteo Bolis

showing 3 related works from this author

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

2017

0301 basic medicinemedicine.medical_specialtyhepacivirusHCV RASTreatment outcomeDrug ResistanceHCV genotypesDrug resistanceBiologyNS5A03 medical and health sciences0302 clinical medicineSecond linedrug resistance viral; humans; retreatment; treatment outcome; antiviral agents; hepacivirus; hepatitis c chronicInternal medicineDrug Resistance Viral; Humans; Retreatment; Treatment Outcome; Antiviral Agents; Hepacivirus; Hepatitis C ChronicDrug Resistance Viralantiviral agentsmedicineViralChronicNS5AhumansHepatologyhepatitis c chronicHepatitis CHepatitis C ChronicSettore MED/07 - Microbiologia e Microbiologia Clinicamedicine.diseaseHepatitis CVirologyHepatology HCV NS5A030104 developmental biologyHCVtreatment outcome030211 gastroenterology & hepatologyretreatmentdrug resistance viral
researchProduct

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

2017

Background Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with telaprevir (TVR)+PR. Study design Mathematical modeling of ALT and HCV-RNA kinetics was performed in 111 HCV-1 cirrhotic patients, 81 treated with all-DAA regimens and 30 with TVR+PR. Kinetic-models and Cox-analysis were used to assess determinants of ALT-decay and normalization. Results HCV-RNA kinetics was biphasic, reflecting …

Genetics and Molecular Biology (all)SimeprevirMaleHepacivirusHepacivirusPharmacologyBiochemistryStiffness0302 clinical medicineAnimal CellsMedicineAmino Acidslcsh:ScienceAlanineOrganic CompoundsLiver Diseases3. Good healthCirrhosisPhysical SciencesAdministrationInterferon030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesOligopeptidesHumanOralMaterials ScienceGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansAgedKineticPharmacologyHepaciviruBiochemistry Genetics and Molecular Biology (all)Mathematical Modelinglcsh:RChemical CompoundsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseasesAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)030104 developmental biologyAgricultural and Biological Sciences (all)chemistryAliphatic Amino Acidslcsh:Q0301 basic medicineSofosbuvirlcsh:MedicineAdministration OralMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Viral Nonstructural ProteinsTelaprevirchemistry.chemical_compoundSimeprevirMedicine and Health SciencesViralMultidisciplinarybiologyAntimicrobialsMedicine (all)Simulation and ModelingDrugsAlanine TransaminaseHepatitis CMiddle AgedAntiviralsHepatitis CChemistryTreatment OutcomeLiverCombinationOligopeptideRNA ViralFemaleAnatomymedicine.drugResearch ArticleSettore MED/17 - Malattie InfettiveGeneral Science & TechnologyMaterial PropertiesResearch and Analysis MethodsMicrobial ControlVirologyRibavirinMechanical PropertiesNS5AAntiviral Agentbusiness.industryRibavirinHCV DAA ALTViral Nonstructural ProteinOrganic ChemistryCell Biologybiology.organism_classificationKineticsAlanine transaminaseAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteinsbiology.proteinHepatocytesRNAInterferonsSofosbuvirbusiness
researchProduct

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

2018

AbstractNatural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mai…

Male0301 basic medicineSofosbuvirHepacivirusDrug Resistancelcsh:MedicineHepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyHepatitis C Virus; HCV resistance-testchemistry.chemical_compound0302 clinical medicineGenotypePrevalenceVirallcsh:ScienceHCV resistance-testMultidisciplinarybiologyHepatitis CMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCohortHCVFemale030211 gastroenterology & hepatologymedicine.drugAdultmedicine.medical_specialtyHepatitis C VirusGenotypeHCV RASHepatitis C virus03 medical and health sciencesInternal medicineDrug Resistance ViralmedicineHumansAdult; Aged; Drug Resistance Viral; Female; Hepacivirus; Hepatitis C; Humans; Italy; Male; Middle Aged; Prevalence; Viral Nonstructural Proteins; GenotypeNS5ANS5BAgedbusiness.industrylcsh:RHepatitis C Virus HCV resistance-testbiology.organism_classificationmedicine.disease030104 developmental biologychemistrylcsh:Qbusiness
researchProduct